Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The ...

In a report released today, from Oppenheimer maintained a Buy rating on Amgen, with a price target of $380.00. The company’s shares closed yesterday at $300.08. Elevate Your Inv ...

Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a ...

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen today. The company’s shares closed yesterday at $300.08. Elevate Your Investing Strategy: Take ad ...

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid. Lastly, the biotech's annualized yield now sits at an all-time high.

Dec 12 (Reuters) - Amgen Inc (AMGN.O) on Monday agreed to buy Horizon Therapeutics Plc (HZNP.O) in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in ...